-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since April, there have been continuous news of cooperation between pharmaceutical industry companies.
For example, ViGeneron and Regeneron have reached a research and development cooperation on the development of a new generation of ophthalmic gene therapy; Hebo Medicine and AstraZeneca: awarded the latter to the development and commercialization of HBM7022; Cooperation with China Resources Pharma on mRNA vaccine business, etc.
, mainly focuses on vaccines, gene therapy, testing and other fields
.
ViGeneron and Regeneron: Reaching a R&D Collaboration to Develop Next-Generation Ophthalmic Gene Therapy Recently, gene therapy company ViGeneron announced that the company and Regeneron have entered into a research and development cooperation agreement for specific targets
.
The parties will develop and commercialize a gene therapy for an inherited retinal disease based on ViGeneron's engineered recombinant adeno-associated virus vector
.
Harbin Pharmaceutical and AstraZeneca: Grant the latter HBM7022 development and commercialization On April 7, Harbin Pharmaceutical announced that the company and AstraZeneca entered into an external licensing agreement to develop and commercialize the antigen bispecific antibody HBM7022
.
Under the agreement, AstraZeneca will receive an exclusive worldwide license for the research, development, registration, manufacturing and commercialization of HBM7022, and will be responsible for all costs associated with further preclinical development and commercialization of HBM7022
.
Harpoon will receive an upfront payment of $25 million and milestone payments of up to $325 million, as well as royalties based on future sales of HBM7022
.
Genting Xinyao and China Resources Pharma: Cooperation on mRNA Vaccine Business Today, Genting Xinyao announced that it has signed a memorandum of cooperation with China Resources Pharma to establish an independent company focused on the discovery, development and commercialization of mRNA vaccines
.
In addition, China Resources Pharmaceutical Group plans to make a strategic equity investment in Genting Xinyao's mRNA technology platform
.
Aide Bio and Chi-Med: Achieving Targeted Drug Clinical Research Cooperation On April 7, Aide announced that the company recently signed a cooperation agreement with Chi-Med
.
The company will work with Chi-Med to promote the registration of the companion diagnostic reagents independently developed by the company in the Chinese market for the treatment of non-small cell lung cancer with the combination therapy of sivotinib and osimertinib mesylate tablets
.
According to reports, the company strictly abides by national laws and industry norms in the field of tumor companion diagnostics, and has built a complete, multi-technology platform-based overall solution for accurate diagnosis, which fully covers lung cancer, colorectal cancer, breast cancer, ovarian cancer and other solid tumors as well as leukemia companion diagnostic needs
.
This time, Chi-Med selected the company as its clinical companion diagnostic partner in China, which is conducive to further enhancing the company's competitiveness in the tumor precision medicine market
.
Yuanxin Technology and Shengfang Pharmaceutical reached cooperation in real-world research and other fields.
On April 6, Yuanxin Technology and Shengfang Pharmaceutical R&D jointly announced that the two parties formally reached a strategic cooperation agreement
.
According to the agreement, the two parties will carry out in-depth cooperation in real-world research and other fields.
The two parties will give full play to their respective advantages, further enrich clinical research methods, accelerate the process of new drug research and development and the transformation of achievements, and help the high-quality development of the industry
.
Wanfu Biotech and General Technology China Pharmaceutical reached a strategic cooperation Wanfu Biological announced on April 5 that on April 1, General Technology China Pharmaceutical signed a strategic cooperation agreement with the company.
The two parties will focus on the marketing of antigen detection reagent products and the business of medical devices.
, project promotion, international trade and other business cooperation
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
For example, ViGeneron and Regeneron have reached a research and development cooperation on the development of a new generation of ophthalmic gene therapy; Hebo Medicine and AstraZeneca: awarded the latter to the development and commercialization of HBM7022; Cooperation with China Resources Pharma on mRNA vaccine business, etc.
, mainly focuses on vaccines, gene therapy, testing and other fields
.
ViGeneron and Regeneron: Reaching a R&D Collaboration to Develop Next-Generation Ophthalmic Gene Therapy Recently, gene therapy company ViGeneron announced that the company and Regeneron have entered into a research and development cooperation agreement for specific targets
.
The parties will develop and commercialize a gene therapy for an inherited retinal disease based on ViGeneron's engineered recombinant adeno-associated virus vector
.
Harbin Pharmaceutical and AstraZeneca: Grant the latter HBM7022 development and commercialization On April 7, Harbin Pharmaceutical announced that the company and AstraZeneca entered into an external licensing agreement to develop and commercialize the antigen bispecific antibody HBM7022
.
Under the agreement, AstraZeneca will receive an exclusive worldwide license for the research, development, registration, manufacturing and commercialization of HBM7022, and will be responsible for all costs associated with further preclinical development and commercialization of HBM7022
.
Harpoon will receive an upfront payment of $25 million and milestone payments of up to $325 million, as well as royalties based on future sales of HBM7022
.
Genting Xinyao and China Resources Pharma: Cooperation on mRNA Vaccine Business Today, Genting Xinyao announced that it has signed a memorandum of cooperation with China Resources Pharma to establish an independent company focused on the discovery, development and commercialization of mRNA vaccines
.
In addition, China Resources Pharmaceutical Group plans to make a strategic equity investment in Genting Xinyao's mRNA technology platform
.
Aide Bio and Chi-Med: Achieving Targeted Drug Clinical Research Cooperation On April 7, Aide announced that the company recently signed a cooperation agreement with Chi-Med
.
The company will work with Chi-Med to promote the registration of the companion diagnostic reagents independently developed by the company in the Chinese market for the treatment of non-small cell lung cancer with the combination therapy of sivotinib and osimertinib mesylate tablets
.
According to reports, the company strictly abides by national laws and industry norms in the field of tumor companion diagnostics, and has built a complete, multi-technology platform-based overall solution for accurate diagnosis, which fully covers lung cancer, colorectal cancer, breast cancer, ovarian cancer and other solid tumors as well as leukemia companion diagnostic needs
.
This time, Chi-Med selected the company as its clinical companion diagnostic partner in China, which is conducive to further enhancing the company's competitiveness in the tumor precision medicine market
.
Yuanxin Technology and Shengfang Pharmaceutical reached cooperation in real-world research and other fields.
On April 6, Yuanxin Technology and Shengfang Pharmaceutical R&D jointly announced that the two parties formally reached a strategic cooperation agreement
.
According to the agreement, the two parties will carry out in-depth cooperation in real-world research and other fields.
The two parties will give full play to their respective advantages, further enrich clinical research methods, accelerate the process of new drug research and development and the transformation of achievements, and help the high-quality development of the industry
.
Wanfu Biotech and General Technology China Pharmaceutical reached a strategic cooperation Wanfu Biological announced on April 5 that on April 1, General Technology China Pharmaceutical signed a strategic cooperation agreement with the company.
The two parties will focus on the marketing of antigen detection reagent products and the business of medical devices.
, project promotion, international trade and other business cooperation
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
